Inosine reduces inflammation and improves survival in a murine model of colitis.
Inosine, a naturally occurring purine formed from the breakdown of adenosine, has recently been shown to exert powerful anti-inflammatory effects both in vivo and in vitro. This study evaluated inosine as a potential therapy for colitis. Colitis was induced in mice by the administration of dextran sulfate sodium (DSS). Oral treatment with inosine was begun either before the onset of colitis or as a posttreatment once colitis was established. Evaluation of colon damage and inflammation was determined grossly (body wt, rectal bleeding), histologically, and biochemically (colon levels of MPO, MDA, and cytokines). DSS-induced colitis significantly increased inflammatory cell infiltration into the colon. DSS-induced colitis also increased colon levels of lipid peroxidation, cytokines, and chemokines. Inosine protected the colon from DSS-induced inflammatory cell infiltration and lipid peroxidation. Inosine also partially reduced these parameters in an experimental model of established colitis. Thus inosine treatment may be a potential therapy in colitis.
Mabley
J G
JG
Inotek Pharmaceuticals, Beverly, Massachusetts 01915, USA. jmabley@inotekcorp.com
Pacher
P
P
Liaudet
L
L
Soriano
F G
FG
Haskó
G
G
Marton
A
A
Szabo
C
C
Salzman
A L
AL
D000818:Animals; D000925:Anticoagulants; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D003106:Colon / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D007288:Inosine / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015996:Survival Rate
D000925:Anticoagulants; D016207:Cytokines; D007288:Inosine; D016264:Dextran Sulfate